Wounds – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Wounds – Pipeline Review, H1 2017’, provides an overview of the Wounds pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Wounds, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wounds and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Wounds

The report reviews pipeline therapeutics for Wounds by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Wounds therapeutics and enlists all their major and minor projects

The report assesses Wounds therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Wounds

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Wounds

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Wounds pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AlgiPharma AS

Alliance Pharma Plc

AmpliPhi Biosciences Corp

AndroScience Corp

Anterogen Co Ltd

Aridis Pharmaceuticals LLC

Beech Tree Labs Inc

Bio3 Research Srl

Biotec Pharmacon ASA

Blueberry Therapeutics Ltd

Cellphire Inc

Chiesi Farmaceutici SpA

CorMedix Inc

Dermala Inc

Destiny Pharma Ltd

Escape Therapeutics Inc

EyeGene Inc

FibroGen Inc

Foresee Pharmaceuticals LLC

Gene Signal International SA

GlaxoSmithKline Plc

IC-MedTech Inc

Living Cell Technologies Ltd

Madam Therapeutics BV

miRagen Therapeutics Inc

NatureWise Biotech & Medicals Corp

Novan Inc

Octapharma AG

Omeros Corp

Osiris Therapeutics Inc

Pacific Northwest Biotechnology LLC

ProMetic Life Sciences Inc

RMB-Research GmbH

RXi Pharmaceuticals Corp

SomaGenics Inc

Stratatech Corp

Synedgen Inc

Thesan Pharmaceuticals Inc

Topadur Pharma AG

Traverse Biosciences Inc

Tumorend LLC

Vascular BioSciences

viDA Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Wounds - Overview 9

Wounds - Therapeutics Development 10

Pipeline Overview 10

Pipeline by Companies 11

Pipeline by Universities/Institutes 16

Products under Development by Companies 18

Products under Development by Universities/Institutes 22

Wounds - Therapeutics Assessment 23

Assessment by Target 23

Assessment by Mechanism of Action 26

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Wounds - Companies Involved in Therapeutics Development 33

AlgiPharma AS 33

Alliance Pharma Plc 33

AmpliPhi Biosciences Corp 33

AndroScience Corp 34

Anterogen Co Ltd 34

Aridis Pharmaceuticals LLC 35

Beech Tree Labs Inc 35

Bio3 Research Srl 35

Biotec Pharmacon ASA 36

Blueberry Therapeutics Ltd 36

Cellphire Inc 36

Chiesi Farmaceutici SpA 37

CorMedix Inc 37

Dermala Inc 38

Destiny Pharma Ltd 38

Escape Therapeutics Inc 38

EyeGene Inc 39

FibroGen Inc 39

Foresee Pharmaceuticals LLC 40

Gene Signal International SA 40

GlaxoSmithKline Plc 40

IC-MedTech Inc 41

Living Cell Technologies Ltd 41

Madam Therapeutics BV 42

miRagen Therapeutics Inc 42

NatureWise Biotech & Medicals Corp 43

Novan Inc 43

Octapharma AG 44

Omeros Corp 44

Osiris Therapeutics Inc 44

Pacific Northwest Biotechnology LLC 45

ProMetic Life Sciences Inc 45

RMB-Research GmbH 46

RXi Pharmaceuticals Corp 46

SomaGenics Inc 47

Stratatech Corp 47

Synedgen Inc 47

Thesan Pharmaceuticals Inc 48

Topadur Pharma AG 48

Traverse Biosciences Inc 48

Tumorend LLC 49

Vascular BioSciences 49

viDA Therapeutics Inc 49

Wounds - Drug Profiles 51

(cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile 51

A-3APO - Drug Profile 52

ABSA-01 - Drug Profile 54

AGL-110 - Drug Profile 58

ALLO-ASC - Drug Profile 59

AlloGraf - Drug Profile 61

Antisense RNAi Oligonucleotide to Inhibit Fidgetin-like 2 for Wound Healing - Drug Profile 62

APO-1 - Drug Profile 63

APO-2 - Drug Profile 64

AR-101 - Drug Profile 65

Arginine Butyrate - Drug Profile 66

ARN-077 - Drug Profile 67

ASCJ-9 - Drug Profile 68

AyuV-25 - Drug Profile 70

B-244 - Drug Profile 71

BB-1000 - Drug Profile 73

BDM-I - Drug Profile 74

BTL-slo - Drug Profile 77

CAR Peptide - Drug Profile 79

Cell Therapy for Dermatology and Immunology - Drug Profile 80

CM-101 - Drug Profile 82

CRMD-004 - Drug Profile 83

CTR-2 - Drug Profile 84

daprodustat - Drug Profile 85

DB-2121 - Drug Profile 88

Drug to Antagonize Beta 2 Receptor for Wounds - Drug Profile 89

Drugs to Agonize Hepatocyte Growth Factor Receptor for Wounds - Drug Profile 90

Drugs to Inhibit 11beta-HSD1 for Wound Healing - Drug Profile 91

EGS-001 - Drug Profile 92

FG-6874 - Drug Profile 93

FP-025 - Drug Profile 94

G-3KL - Drug Profile 95

Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 96

Gene Therapy to Activate HSP60 for Wounds - Drug Profile 97

GS-156 - Drug Profile 98

Human Growth Factor - Drug Profile 99

hVGF - Drug Profile 100

JM-2 CR - Drug Profile 101

LWnt-3a - Drug Profile 102

MG-53 - Drug Profile 103

MMP-26051 - Drug Profile 105

MMP-26052 - Drug Profile 106

molgramostim - Drug Profile 107

Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile 108

MRG-110 - Drug Profile 109

NBM-67 - Drug Profile 110

ND-336 - Drug Profile 111

NTCELL - Drug Profile 112

Oligomer G for Burn Wounds - Drug Profile 117

OTI-1011 - Drug Profile 118

OTI-1502 - Drug Profile 119

P-148 - Drug Profile 120

Panaecin - Drug Profile 121

Peptides for Wounds - Drug Profile 122

Perlecan - Drug Profile 123

PGF - Drug Profile 125

plasminogen (recombinant) - Drug Profile 126

Polysaccharide for Wounds and Scars - Drug Profile 127

Protein for Hematological Disorders, Dermatology, Shock, Injury, Trauma and Infectious Disease - Drug Profile 128

Protein for Infectious Disease, Wounds and Skin Infections - Drug Profile 129

Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile 130

Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile 131

Recombinant Protein to Activate Fibroblast Growth Factor for Wounds - Drug Profile 132

Recombinant Protein to Agonize FGFR2 for Wounds - Drug Profile 133

Recombinant Protein to Agonize NGFR for Wounds - Drug Profile 134

Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile 135

Recombinant Protein to Target MMP-9 for Wounds - Drug Profile 136

Recombinant Proteins for Diabetic Wound Healing - Drug Profile 137

RT-1740 - Drug Profile 138

SFR-9X0125 - Drug Profile 139

SG-404 - Drug Profile 140

silver sulfadiazine - Drug Profile 141

Small Molecule for MRSA Skin Infection and Wound Healing - Drug Profile 142

Small Molecule to Activate MRTF-A for Wound Healing - Drug Profile 143

Small Molecule to Target LGR6 for Dermatology - Drug Profile 144

Small Molecules for Staphylococcal Infections and Wounds - Drug Profile 145

Small Molecules to Activate iRhom2 for Wound Healing and Oncology - Drug Profile 146

Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 147

Soluble Beta Glucan - Drug Profile 148

Statmicoll - Drug Profile 151

Stm Cell Therapy for Chronic Wounds - Drug Profile 152

Synthetic Peptide to Antagonize CD168 for Dermatology, Musculoskeletal, Oncology and Respiratory Disorders - Drug Profile 153

Synthetic Peptides for Bacterial Keratitis and Wounds - Drug Profile 154

Synthetic Peptides for Wound Healing and Neurodegenerative Diseases - Drug Profile 155

Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 156

Thrombosomes - Drug Profile 158

Tolecine - Drug Profile 159

TOPN-53 - Drug Profile 160

TRBN-0224 - Drug Profile 161

TWB-103 - Drug Profile 163

V-2248 - Drug Profile 164

VTI-3000 Series - Drug Profile 165

WH-1 - Drug Profile 166

XF-70 - Drug Profile 167

Wounds - Dormant Projects 168

Wounds - Discontinued Products 173

Wounds - Product Development Milestones 174

Featured News & Press Releases 174

Appendix 179

Methodology 179

Coverage 179

Secondary Research 179

Primary Research 179

Expert Panel Validation 179

Contact Us 179

Disclaimer 180

List of Tables

List of Tables

Number of Products under Development for Wounds, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Wounds – Pipeline by AlgiPharma AS, H1 2017

Wounds – Pipeline by Alliance Pharma Plc, H1 2017

Wounds – Pipeline by AmpliPhi Biosciences Corp, H1 2017

Wounds – Pipeline by AndroScience Corp, H1 2017

Wounds – Pipeline by Anterogen Co Ltd, H1 2017

Wounds – Pipeline by Aridis Pharmaceuticals LLC, H1 2017

Wounds – Pipeline by Beech Tree Labs Inc, H1 2017

Wounds – Pipeline by Bio3 Research Srl, H1 2017

Wounds – Pipeline by Biotec Pharmacon ASA, H1 2017

Wounds – Pipeline by Blueberry Therapeutics Ltd, H1 2017

Wounds – Pipeline by Cellphire Inc, H1 2017

Wounds – Pipeline by Chiesi Farmaceutici SpA, H1 2017

Wounds – Pipeline by CorMedix Inc, H1 2017

Wounds – Pipeline by Dermala Inc, H1 2017

Wounds – Pipeline by Destiny Pharma Ltd, H1 2017

Wounds – Pipeline by Escape Therapeutics Inc, H1 2017

Wounds – Pipeline by EyeGene Inc, H1 2017

Wounds – Pipeline by FibroGen Inc, H1 2017

Wounds – Pipeline by Foresee Pharmaceuticals LLC, H1 2017

Wounds – Pipeline by Gene Signal International SA, H1 2017

Wounds – Pipeline by GlaxoSmithKline Plc, H1 2017

Wounds – Pipeline by IC-MedTech Inc, H1 2017

Wounds – Pipeline by Living Cell Technologies Ltd, H1 2017

Wounds – Pipeline by Madam Therapeutics BV, H1 2017

Wounds – Pipeline by miRagen Therapeutics Inc, H1 2017

Wounds – Pipeline by NatureWise Biotech & Medicals Corp, H1 2017

Wounds – Pipeline by Novan Inc, H1 2017

Wounds – Pipeline by Octapharma AG, H1 2017

Wounds – Pipeline by Omeros Corp, H1 2017

Wounds – Pipeline by Osiris Therapeutics Inc, H1 2017

Wounds – Pipeline by Pacific Northwest Biotechnology LLC, H1 2017

Wounds – Pipeline by ProMetic Life Sciences Inc, H1 2017

Wounds – Pipeline by RMB-Research GmbH, H1 2017

Wounds – Pipeline by RXi Pharmaceuticals Corp, H1 2017

Wounds – Pipeline by SomaGenics Inc, H1 2017

Wounds – Pipeline by Stratatech Corp, H1 2017

Wounds – Pipeline by Synedgen Inc, H1 2017

Wounds – Pipeline by Thesan Pharmaceuticals Inc, H1 2017

Wounds – Pipeline by Topadur Pharma AG, H1 2017

Wounds – Pipeline by Traverse Biosciences Inc, H1 2017

Wounds – Pipeline by Tumorend LLC, H1 2017

Wounds – Pipeline by Vascular BioSciences, H1 2017

Wounds – Pipeline by viDA Therapeutics Inc, H1 2017

Wounds – Dormant Projects, H1 2017

Wounds – Dormant Projects, H1 2017 (Contd..1), H1 2017

Wounds – Dormant Projects, H1 2017 (Contd..2), H1 2017

Wounds – Dormant Projects, H1 2017 (Contd..3), H1 2017

Wounds – Dormant Projects, H1 2017 (Contd..4), H1 2017

Wounds – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Wounds, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports